Neurological and psychiatric tolerability of rilpivirine (TMC278)vs.efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks-Reference-Cited by-同舟云学术

Neurological and psychiatric tolerability of rilpivirine (TMC278)vs.efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks

Published:2013-01-09 Issue:7 Volume:14 Page:391-400
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Mills AM¹,Antinori A²,Clotet B³,Fourie J⁴,Herrera G⁵,Hicks C⁶,Madruga JV⁷,Vanveggel S⁸,Stevens M⁸,Boven K⁹,

Affiliation:

1. Anthony Mills MD Inc.; Los Angeles; CA; USA

2. National Institute for Infectious Diseases ‘Lazzaro Spallanzani’ IRCCS; Rome; Italy

3. University Hospital Germans Trias i Pujol and irsiCaixa Foundation; UAB; Barcelona; Spain

4. Dr J Fourie Medical Centre; Dundee; KwaZulu Natal; South Africa

5. Hospital CIMA San Jose; San Jose; Costa Rica

6. Division of Infectious Diseases; Duke University Medical Center; Durham; NC; USA

7. Centro de Referência e Treinamento DST/AIDS; São Paulo; Brazil

8. Janssen Infectious Diseases BVBA; Beerse; Belgium

9. Janssen Research & Development; LLC; Titusville; NJ; USA

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference51 articles.

1. Adherence to HAART regimens;Chesney;AIDS Patient Care STDS,2003

2. HIV patient insight on adhering to medication: a qualitative analysis;Beusterien;AIDS Care,2008

3. Hawker J Mah Ming J Krentz H et al Antiretroviral discontinuation due to adverse effects in a population-based HIV/AIDS treatment database 17 th Annual Canadian Conference on HIV/AIDS Research 2008

4. Patient preferences among third agent HIV medications: a US and German perspective;Beusterien;AIDS Care,2007

5. Determinants of discontinuation of highly active antiretroviral therapy regimens in a US HIV-infected patient cohort;Yuan;HIV Med,2006

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comorbidity and polypharmacy among people with HIV stratified by age, sex, and race;HIV Research & Clinical Practice;2024-05-30

2. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study;Journal of Medical Virology;2023-10

3. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV;Expert Opinion on Pharmacotherapy;2022-09-02

4. Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV;AIDS Research and Human Retroviruses;2022-07-01

5. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis;International Journal of Antimicrobial Agents;2022-01